Company Information
Industry 制造业
Company Introduction 南京伟思医疗科技股份有限公司成立于2001年,是中国康复医疗器械行业的技术创新驱动型企业,致力于在盆底及产后康复、神经康复、精神康复等细分领域为医院等专业机构提供安全、有效的康复产品及整体解决方案。目前公司产品主要包括生物刺激反馈仪、磁刺激仪等,涵盖电刺激、磁刺激、电生理等技术方向;此外,公司还正在进行下一代磁刺激仪、康复机器人等新产品的研发。 公司定位于中国康复市场,并聚焦于电刺激、磁刺激、电生理等细分市场,公司凭借多年来对于市场的理解和投入,坚持以研发创新为发展驱动力,坚持引领产业及技术前沿的战略定位,打造了坚实和多样的技术平台和具备竞争力的产品解决方案,建立了覆盖全国的销售渠道网络布局,塑造了良好的品牌形象和学术推广体系,完善了以客户满意为中心的客户服务体系,使得公司在技术、产品、渠道、品牌和服务等方面形成了综合性的竞争优势,保持了较高的市场占有率。 未来,公司将紧紧抓住康复医疗器械市场快速发展的良好契机,面向产业前沿领域持续加大自主创新投入,持续提升公司在技术、产品、渠道、品牌和服务方面的竞争优势,扩大产品覆盖和市场覆盖,力争发展成为国际领先的康复医疗器械公司。
Main Business 医疗器械的研发、生产和销售。
Legal Representative 王志愚
Top Executives
董事长:王志愚
董事:张辉,陈莉莉,许金国,王志愚
独立董事:蔡卫华,肖俊方,吴家璐
Top 5 Shareholder
Shareholder name Nature Holding Date
王志愚流通A股39.46%30/09/2024
胡平流通A股16.41%30/09/2024
南京志达创业投资中心(有限合伙)流通A股8.29%30/09/2024
深圳市阳和生物医药产业投资有限公司流通A股2.60%30/09/2024
中国工商银行股份有限公司-融通健康产业灵活配置混合型证券投资基金流通A股1.98%30/09/2024
Company Secretary 钟益群
Solicitors 江苏世纪同仁律师事务所
Auditors 天衡会计师事务所(特殊普通合伙)
Tel No 025-69670036
Fax No 025-69670037
Website www.vishee.com
Email ir@vishee.com
Company Address
Register: 江苏省南京市雨花台区宁双路19号9栋
Office: 江苏省南京市雨花台区宁双路19号9栋
Listing Date 21/07/2020
Shares Capital
Shares Capital: 95,771,288
Total A Share: 95,771,288
Listed A Share: 95,771,288
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.997
DPS(RMB)* ¥ 1.506
NBV Per Share(RMB)* ¥ 23.705
Market Capitalization(RMB) 2.869B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.